Skip to main content

Table 3 The effect of the type of drug resistance or history of TB treatment on the proportion of treatment success of the two groups

From: Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China

Indicators

BDQ group (n = 102)

 

Non-BDQ group (n = 100)

 

p value

 

Success

Others

Success

Others

 

Type of drug resistance (n, %)

     

 RR

3 (100.0)

0 (0.0)

2 (40.0)

3 (60.0)

0.20

 MDR

69 (93.2)

5 (6.8)

47 (69.1)

21 (30.9)

< 0.001*

 XDR

22 (88.0)

3 (12.0)

14 (51.9)

13 (48.1)

0.005*

History of TB treatment (n, %)

     

 New cases

10 (90.9)

1 (9.1)

6 (75.0)

2 (25.0)

0.55

 One-time history of TB treatment

34 (91.9)

3 (8.1)

18 (72.0)

7 (28.0)

0.04*

 Two-time history of TB treatment

29 (90.6)

3 (9.4)

27 (71.1)

11 (28.9)

0.04*

 ≥ Three-time history of TB treatment

21 (95.5)

1 (4.5)

12 (41.4)

17 (58.6)

< 0.001*

 MDR/RR-TB

(n = 77)

 

(n = 73)

  

 New cases

7 (100.0)

0 (0.0)

5 (71.4)

2 (28.6)

0.46

 One-time history of TB treatment

30 (90.9)

3 (9.1)

16 (76.2)

5 (23.8)

0.14

 Two-time history of TB treatment

21 (95.5)

1 (4.5)

20 (76.9)

6 (23.1)

0.07

 ≥ Three-time history of TB treatment

14 (93.3)

1 (6.7)

8 (42.1)

11 (57.9)

0.003*

 XDR-TB

(n = 25)

 

(n = 27)

  

 New cases

3 (75.0)

1 (25.0)

1 (100.0)

0 (0.0)

1.00

 One-time history of TB treatment

4 (100.0)

0 (0.0)

2 (50.0)

2 (50.0)

0.432

 Two-time history of TB treatment

8 (80.0)

2 (20.0)

7 (77.8)

5 (22.2)

1.00

 ≥ Three-time history of TB treatment

7 (100.0)

0 (0.0)

4 (40.0)

6 (60.0)

0.04*

  1. TB tuberculosis, n number, RR rifampicin-resistant, MDR multidrug-resistant, XDR extensively drug-resistant, BDQ bedaquiline
  2. * the differences had statistical significance (p < 0.05)